Short answer
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $46M (up 10.1% year over year) with net income of −$14M.
Q3 2026 key financials · XBRL
- Revenue
- $46M
- +10.1% YoY · −10.9% QoQ
- Net income
- −$14M
- +45.8% YoY · −11.5% QoQ
- Operating margin
- -45.0%
- Gross margin
- 35.3%
- EPS (diluted)
- −$0.09
- +50.0% YoY · +0.0% QoQ
Source: XBRL data from the MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) Q3 2026 10-Q on SEC EDGAR. USD.
MARAVAI LIFESCIENCES HOLDINGS, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $45.9M, up 10.1% YoY from $41.6M
- Gross margin 35.3% vs 13.6% YoY, net loss $24.0M vs $45.1M
- Best segment TriLink: $28.4M, up 11.8%; Cygnus $17.5M, up 7.5%
- Operating cash flow $17.7M vs $(34.8)M YoY; cash $73.0M at September 30
- No further high-volume CleanCap COVID orders expected in 2026; 2027 binding orders absent
Risk Factors
- No material changes to previously disclosed risk factors since the December 31, 2025 Form 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MARAVAI LIFESCIENCES HOLDINGS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.